Omada Health, Inc. (NASDAQ:OMDA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Omada Health, Inc. (NASDAQ:OMDA) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $22.90.

Several research firms have recently weighed in on OMDA. Wells Fargo & Company assumed coverage on Omada Health in a research note on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 price objective on the stock. The Goldman Sachs Group restated a “buy” rating and issued a $26.00 price target on shares of Omada Health in a report on Friday, January 16th. Canaccord Genuity Group reduced their price target on shares of Omada Health from $28.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday. Morgan Stanley decreased their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday. Finally, BMO Capital Markets dropped their price objective on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday.

Omada Health Trading Up 3.3%

Shares of OMDA opened at $14.05 on Friday. Omada Health has a twelve month low of $10.28 and a twelve month high of $28.40. The firm has a market capitalization of $813.61 million and a P/E ratio of -56.20. The stock’s fifty day simple moving average is $14.03 and its 200 day simple moving average is $18.67.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million for the quarter.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

Insider Buying and Selling at Omada Health

In other Omada Health news, CEO Sean P. Duffy sold 230,479 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $15.60, for a total value of $3,595,472.40. Following the transaction, the chief executive officer directly owned 126,644 shares of the company’s stock, valued at $1,975,646.40. This trade represents a 64.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Wei-Li Shao sold 5,618 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $16.13, for a total value of $90,618.34. Following the completion of the transaction, the president directly owned 69,079 shares in the company, valued at $1,114,244.27. This trade represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 276,893 shares of company stock worth $4,336,787 in the last 90 days.

Institutional Investors Weigh In On Omada Health

A number of large investors have recently modified their holdings of the stock. Cigna Investments Inc. New purchased a new stake in shares of Omada Health during the 3rd quarter valued at about $76,161,000. Perceptive Advisors LLC acquired a new stake in Omada Health in the second quarter valued at approximately $44,402,000. Millennium Management LLC grew its position in Omada Health by 1,195.0% in the fourth quarter. Millennium Management LLC now owns 2,272,168 shares of the company’s stock valued at $35,855,000 after acquiring an additional 2,096,705 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Omada Health by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,855,721 shares of the company’s stock valued at $29,283,000 after purchasing an additional 346,588 shares during the period. Finally, Divisadero Street Capital Management LP acquired a new position in shares of Omada Health during the third quarter worth $30,510,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.